Top Oil Service Companies To Invest In 2014

There is a lot of buzz over recent energy activity in Sub-Saharan Africa. With Anadarko Petroleum (NYSE: APC  ) and Eni (NYSE: E  ) making large gas finds off the coast of Mozambique, several majors are now looking to get in the game as well. BP plans to spend $540 million over the next five years to develop a part of this gas field that could hold well over 100 trillion cubic feet.�

Better drilling technology and relative political stability in the region have allowed several companies to start investing money in the region, and if some of these plays hit paydirt, some companies could be in for big paydays. In this video, Fool.com contributor Tyler Crowe talks with Aimee Duffy about some of the hot energy plays on the African continent and what we should expect from this region in the years to come. �

With more than 94% of its capital investments coming in the international markets for 2013, National Oilwell Varco is positioning itself to be the leader in oil services around the world. To help determine whether it could be a good fit for your portfolio, you're invited to check out The Motley Fool's premium research report featuring in-depth analysis on whether NOV is a buy today. For instant access to this valuable investor's resource, simply click here now to claim your copy.

10 Best Managed Healthcare Stocks For 2015: XOMA Ltd.(XOMA)

XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. Its products under development include gevokizumab, an anti-inflammatory monoclonal antibody that inhibits interleukin-1 beta and has completed Phase 2 development stage for the treatment of Behcet?s uveitis, as well as is in Phase 2b clinical trail for Type 2 diabetes with cardiovascular biomarkers; XOMA 3AB, a biodefense anti-botulism product candidate comprising a combination or cocktail of antibodies for the treatment of botulism poisoning; and preclinical antibody discovery programs in various indications, including autoimmune, cardio-metabolic, inflammatory, and oncological diseases. The company, through its collaboration agreement with Novartis AG, is also developing HCD122, a human anti-CD40 antagonist antibody that is in Phase 1/2 clinical trial for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases; and LFA102, which is in Phase 2 clinical trial for the treatment of hematologic tumors and other undisclosed diseases. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; SRI International; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; Genentech, Inc.; and UCB Celltech. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California.

Advisors' Opinion:

• [By Lisa Levin]

  XOMA (NASDAQ: XOMA) shares reached a new 52-week high of $8.61. XOMA shares have jumped 196.09% over the past 52 weeks, while the S&P 500 index has gained 25.27% in the same period.

• [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]

  XOMA Corp.(XOMA) said it swung to a loss in the fourth quarter, as an increase in operating expenses offset revenue gains. The drug developer’s losses were wider than expected by the market, sending shares down 20% to $7.54 premarket.

• [By Ben Fox Rubin]

  Xoma Corp.(XOMA) announced it plans to sell shares of its common stock, though it didn’t say how many. The drug developer recently had about 93.1 million shares outstanding, according to FactSet. Shares fell 8.3% to $5.19 premarket.

Top Oil Service Companies To Invest In 2014: Canadian Imperial Bank of Commerce(CM)

Canadian Imperial Bank of Commerce provides various financial products, services, and advice to individual, small business, commercial, corporate, and institutional clients in Canada and internationally. The company offers retail markets services comprising personal banking, business banking, and wealth management services, as well as investment management services to retail and institutional clients. It also provides wholesale banking services, including credit, capital markets, investment banking, merchant banking, and research products and services to government, institutional, corporate, and retail clients. The company provides its services through its branch network, automated bank machines, mobile banking, and online banking site. As of June 3, 2011, it operated approximately 1,100 branches and 4,000 automated bank machines in Canada. The company was founded in 1867 and is headquartered in Toronto, Canada.

Advisors' Opinion:

• [By Tony Daltorio]

  One of his companies, Cheung Kong Holdings Limited (CHEUY), recently formed a 50/50 joint venture with Canadian Imperial Bank of Commerce (NYSE: CM) called CEF Holdings. They want to invest into beaten-down mining stocks and particularly gold equities.

• [By Arie Goren]

  Canadian Imperial Bank of Commerce (CM)

  Canadian Imperial Bank of Commerce provides various financial products and services in Canada and internationally.

Top Oil Service Companies To Invest In 2014: Cardiome Pharma Corporation(CRME)

Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. The company has a phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C that completed phase I clinical trials for the treatment of infectious disease. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on cardiac diseases, ion channel conditions, and other indications. It also has a collaboration and license agreement with Merck & Co., Inc. (Merck), for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. t o develop, make, and sell intravenous or injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By Roberto Pedone]

   

   

   

  One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Cardiome Pharma (CRME), which engages in the discovery, development and commercialization of therapies that enhance the health of patients. This stock has been on fire over the last three months, with shares up sharply by 43%.

  If you take a look at the chart for Cardiome Pharma, you'll notice that this stock has been trading range bound for the last month or so, with shares moving between $5.85 on the downside and $7.15 on the upside. Shares of CRME have now started to bounce higher off that big support level near $6 a share and it's quickly moving within range of triggering a big breakout trade above some key near-term overhead resistance levels.

  Traders should now look for long-biased trades in CRME if it manages to break out above some near-term overhead resistance levels at $6.95 to its 52-week high at $7.15 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 123,602 shares. If that breakout triggers soon, then CRME will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $9 to $10 a share.

  Traders can look to buy CRME off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $6 or $5.85 or near its 50-day moving average of $5.63 a share. One can also buy CRME off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By John Udovich]

  The biotech sector along with small cap biotech stocks Cardiome Pharma Corp (NASDAQ: CRME), Oncolytics Biotech, Inc (NASDAQ: ONCY), Vital Therapies Inc (NASDAQ: VTL) and TNI BioTech (OTCMKTS: TNIB) have all been producing their share of news this week for investors and traders alike to trade on. Moreover and while some 42 ��ife sciences��companies have gone public raising about $3 billion from investors so far this year, there are a growing number of biotechs pulling the plug on upcoming IPOs who are citing market conditions. With that in mind, here is a look at important news from the biotech sector and small cap biotech stocks this week:

Top Oil Service Companies To Invest In 2014: VASCO Data Security International Inc. (VDSI)

VASCO Data Security International, Inc., through its subsidiaries, engages in the design, development, marketing, and support of hardware and software security systems that manage and secure access to information assets worldwide. The company offers hardware and software products in the areas of user authentication, electronic signatures, and digital signatures/public key infrastructure. It provides VACMAN Controller that supports multiple authentication technologies, including passwords, dynamic password technology, electronic signatures, digital signatures, and certificates and biometrics on one platform. The company also offers IDENTIKEY Server, a centralized authentication server that supports the deployment, use, and administration of DIGIPASS user authentication. In addition, it provides aXs GUARD Identifier, a standalone authentication solution, which offers two-factor authentication for remote access to a corporate network or to Web-based in-house business applicat ions; and aXs GUARD Gatekeeper that integrates DIGIPASS to provide secure two factor user authentication. Further, the company offers DIGIPASS product line exists as a family of software and hardware client authentication products and services for authenticating users to any network, including the Internet. Its DIGIPASS solution calculates dynamic signatures and passwords to authenticate users on a computer network and for various other applications. The DIGIPASS technology is also designed to operate on desktop personal computers or laptops, personal digital assistants, mobile phones, and smart cards. VASCO sells its security solutions through its direct sales force, as well as through distributors, resellers, and systems integrators. The company was founded in 1996 and is headquartered in Oakbrook Terrace, Illinois.

Advisors' Opinion:

• [By Sally Jones]

  
  Vasco Data Security (VDSI): Reduced

  Down 20% over 12 months, Vasco Data Security has a market cap of $316.26 million; its shares were traded at around $8.01 with a P/E ratio of 27.40 and a P/B of 2.00.